Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.60

€0.60

0.770%
0.005
0.770%
€0.45
 
19.07.24 / Tradegate WKN: A2N4RX / Symbol: GRTS / Name: Gritstone Oncology / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Gritstone Oncology Inc Stock

The Gritstone Oncology Inc stock is trending slightly upwards today, with an increase of €0.005 (0.770%) compared to yesterday's price.
Currently there is a rather negative sentiment for Gritstone Oncology Inc with 4 Buy predictions and 20 Sell predictions..
For the coming years our community has positive and negative things to say abot the Gritstone Oncology Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Market Position" there were negative voices in the community.

Pros and Cons of Gritstone Oncology Inc in the next few years

Pros
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Gritstone Oncology Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Gritstone Oncology Inc 0.770% 1.427% -16.632% -69.246% -67.492% -90.496% -
Rockwell Medical Inc. -2.220% -11.523% 1.595% -56.511% -0.807% -74.596% -93.713%
Pacira Pharmaceuticals -5.260% -9.091% -29.688% -45.122% -39.597% -61.373% -48.820%
Avid Bioservices Inc 1.160% 12.987% 26.087% -26.891% 42.623% -58.571% 58.528%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-09

Nur wenige Unternehmen können den Sturm, der sich in der pharmazeutischen Branche abspielt, überleben. Auf der einen Seite stehen die immensen Kosten für Forschung und Entwicklung und auf der anderen Seite der Druck nach mehr bezahlbaren Medikamenten. Für einige Unternehmen, wie Gritstone Oncology (Börsensymbol GRTS), scheint allerdings dieses Szenario eine Gelegenheit zu bieten.

Gritstone Oncology steht finanziell betrachtet vor großen Herausforderungen. Da das Unternehmen noch in der Entwicklungsphase steckt, hat es nur begrenzte Einnahmen aus Produktverkäufen. Gleichzeitig sind die Ausgaben für Forschung und Entwicklung (F&E) – mit Ausgaben von 111,4 Millionen USD, 97,5 Millionen USD und 88,6 Millionen USD in den Jahren 2022, 2021 und 2020 – beträchtlich.

Ein positiver Aspekt der finanziellen Lage von Gritstone Oncology ist die solide Bilanz. Das Unternehmen verfügte zum 31. Dezember 2022 über Vermögenswerte in Höhe von 240,75 Millionen USD und ein Eigenkapital von 170,78 Millionen USD. Das bedeutet, dass das Unternehmen über ausreichende Ressourcen verfügt, um seine laufenden Aktivitäten zu finanzieren.

Comments

Prediction Sell
Perf. (%) -5.33%
Target price 0.500
Change
Ends at 17.07.25

Gritstone Oncology Inc. (GRTS) is facing some legal troubles, with several class action lawsuits filed against the company. This, coupled with the company's recent stock price drop, gives me pause. While the company's technology and pipeline might be promising, the legal uncertainty and financial challenges make me cautious. I'd need to see some positive developments and a more stable financial footing before considering a buy. For now, I think it's best to steer clear and wait for the dust to settle. The target price of $0.50 reflects the risks and uncertainties surrounding the stock.
Show more

Prediction Sell
Perf. (%) -5.48%
Target price 0.450
Change
Ends at 16.07.25

Gritstone Oncology is facing some legal troubles, with multiple class action lawsuits being filed against the company. While the news about inducement grants to employees is positive, the ongoing legal issues raise concerns about the company's stability and future prospects. The current price of $0.6045 seems quite high given these uncertainties, and I believe there's a better chance of the stock price declining further rather than rebounding in the near term. As an investor, I would be cautious and consider selling my position to avoid potential further losses.
Show more

Prediction Sell
Perf. (%) -5.48%
Target price 0.400
Change
Ends at 16.07.25

The recent news and developments surrounding Gritstone Oncology Inc (GRTS) give me pause. The company's announcement of inducement grants for a new employee, while not entirely unexpected, doesn't seem to move the needle much. What's more concerning are the multiple class action lawsuits that have been filed against GRTS by law firms on behalf of investors. These lawsuits allege securities fraud, and the looming deadlines for joining them suggest there could be some merit to the claims. As an investor, I can't help but wonder what skeletons might be lurking in GRTS's closet. Until the company can put these legal issues behind it and provide more clarity on its future prospects, I'm hesitant to invest. The current share price of $0.6045 seems optimistic, and I believe a more realistic target price would be around $0.40. For now, I'd recommend selling or avoiding this stock altogether.
Show more